Bluebox advises on the sale of Infermed

Bluebox Corporate Finance advises
InferMed on its sale to Reed Elsevier PLC.

Bluebox Corporate Finance is delighted to announce the sale of InferMed Limited, a provider of innovative software solutions to the global healthcare industry. The shareholders appointed Bluebox some 18 months ago to prepare the business for sale by running it through the key elements of Bluebox’s award winning ‘Blue Diamond’ programme and then manage the sale exercise when the time arrived. Pricing and other transaction details were not disclosed.

InferMed was initially formed as a joint venture between Cancer Research UK and Integral Solutions Limited, a business previously owned by InferMed’s Chairman, Dr Alan Montgomery. The unique clinical decision support software quickly found a place in the market, being used by both private healthcare companies including Hoffman La Roche and government organisations such as the NHS. The company’s software is now an integral part of the NHS’s operations in relation to improving the accuracy and efficiency of patient diagnosis.

The purchaser, RELX (formerly Reed Elsevier), is a global information solutions provider across a number of industries.

Alan Montgomery, founder and former Chairman of InferMed commented:

“When I first engaged with Bluebox some eighteen months ago, I was drawn by their pre-sale planning programme as I recognised that InferMed had some internal work to complete before being ‘fit for sale’. Bluebox worked closely with us over the following six months and helped us to implement some key initiatives which made InferMed a more attractive acquisition target. Once we decided to sell the business, the Bluebox team were very diligent in ensuring that no stone was left unturned. They negotiated expertly on our behalf to ensure we got the best deal possible”.

Paul Herman, CEO of Bluebox, commented:

“We are delighted with the sale of InferMed to the RELX Group. InferMed created market-leading software which numerous market players recognized immediately as being ‘well ahead of its time’. With a broad base of shareholders, including Cancer Research UK, and the numerous other challenges that had been flagged to us, we knew that a significant amount of work was going to be required to get this deal ‘across the line’. Working alongside Dr Montgomery was a pleasure and we are delighted to have been able to deliver an outcome that represents a good deal for shareholders and leaves the business in capable hands that will allow it to fulfil its potential.”

Back To Success Stories

quote marks icon